REMARKS

Applicants would like to thank the Examiner for the interview granted concerning this application as reflected in INTERVIEW SUMMARY, Paper No. 9. The remarks therein reflect the substance of the interview.

Applicants cancel claims 7-9 and present claims 10 and 11 herein in the form which, it is believed, renders these claims allowable.

Allowance is requested.

If the Examiner has any question, the Examiner is requested to contact the undersigned.

Respectfully submitted,



Peter D. Olexy, P.C.
Registration No. 24,513

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: June 28, 2002

APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Claims 5, 6, 7, 8 and 9 are canceled.

The claims 10 and 11 are amended as follows:

Claim 10 (twice amended). A method for [photokinetically] detecting and treating malignant tumors, which method comprises;

administering a tumor detecting effective amount, to a host in need of [tumor] detection of a malignant tumor, of [a compound] 5-aminolevulinic acid or a derivative thereof in which at least one carbon atom of said 5-aminolevulinic acid is a carbon isotope and/or a nitrogen atom in its amino group is a nitrogen isotope, and where said derivative is an ester, amide, salt, hydrate or solvate of said [compound] 5-aminolevulinic acid;

detecting the malignant tumor[s] using NMR; and

[selectively killing the] administering an effective amount of said 5-aminolevulinic acid or derivative thereof, in which at least one carbon atom of said 5-aminolevulinic acid is a carbon isotope and/or a nitrogen atom in its amino group is a nitrogen isotope, and where said derivative is an ester, amide, salt, hydrate or solvate of said 5-aminolevulinic acid, to kill said malignant tumor[s].

Claim 11 (twice amended) The method of claim 10 wherein said [compound] 5-aminolevulinic acid or derivative thereof is used in combination with a diagnostically acceptable carrier.